Boldenon was developed in 1949 by the pharmaceutical company Ciba and resembles the Dianabol, only the 17α-alkylation missing in the Boldenon distinguishes both. Nevertheless, the effect of the two substances is completely opposite. Boldenon converts about 50 percent less to estrogen in the male body than testosterone. Thus, with simultaneous training, a lean muscle structure without high fat and water content is possible, which is why Boldenon is mainly in a diet or athletes who pursue primarily high-quality muscle construction. Furthermore, Boldenon binds strong erythrocytes, that is, red blood cells that help to striking vascularity.